We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cic Gold Grp | LSE:CICG | London | Ordinary Share | SC0665AHDJ29 | ORD NPV (DI) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.425 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 1.425 | GBX |
Cic Gold Grp (CICG) Share Charts1 Year Cic Gold Grp Chart |
|
1 Month Cic Gold Grp Chart |
Intraday Cic Gold Grp Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 28/3/2024 | 00:32 | CIC Gold Group Limited | 5,004 |
| 22/2/2017 | 14:57 | CICGOLD Group | 4 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 03/1/2024 17:23 by papillon "macnaiPosted in: CICC.L Posts: 400 Price: 0.00 No Opinion Innomed 27 Dec 2023 14:12 Hopefully, they can get a market listing in 2024 but it will be a long road till they can get FDA approval. Here is a link to the FDA site if you want to look and are still in this world and need to look. What of all these other companies Stuart is involved with and will there be any reward for long-suffering CIC shareholders? A similar theme that Stuart has been weaving for years. Live Long and Prosper...." |
Posted at 01/12/2023 15:13 by sparty1 hxxps://www.securitihxxps://www.linkedin |
Posted at 27/7/2023 09:24 by papillon "No you are not but you are still obsessed with Stuart"You're wrong yet again, sparty1! I'm definitely not obsessed with Bromley. Why should I be? I don't know the man (nor would I want to). I'm just being smug and like boasting that I sold all my CICC shares before it was suspended and never bought CICG shares like you and the other mugs did! I don't often get things right, but I did in this case! That's why I like shouting it from the rooftops! 🤣 PS why do you still refer to SB as Stuart? Are you on first name terms with him? Is he a personal friend of yours? 🤣 |
Posted at 26/7/2023 16:20 by sparty1 Paps"Luckily I'm not a shareholder in either CICC, or CICG, sparty1" No you are not but you are still obsessed with Stuart...and you were a shareholder? Shareholders being interested I get. Fraggle must be so excited. :) |
Posted at 26/7/2023 14:22 by ih_158036 CORPORATE UPDATE July 26, 2023InnoMed Tech Ltd is holding Company of medical science companies in the business of creating paradigm shifts in thinking to improve clinical outcomes for medical and surgical patients. The Company’s clinical and business leadership team combines years of experience of corporate, and medical science who along with medical engineers, key advisors, work to solve problems presenting in today’s medical and surgical patient population. Directors Innomed Tec Ltd. (Parent Co): Robert L. Rhodes - Australia (CEO) Terrance A. Larkan - Australia (CFO) Billy Williams - US David Toyoda - Canada Dr Marshall Walker- US Directors PureFlowCath LLC. (US): Dr Matthew Mcintyre Robert L. Rhodes 3 to 2 independent directors Summary of Operations InnoMed Tech Ltd. (the “Company” TSX Venture Exchange Listing Update Innomed Tech Limited (the Company) is pleased to announce that we have been given a waiver for the requirement of appointing a regulated Canadian Listing Sponsor. It is estimate that this will save the Company in the order of CAD$180,000 and remove the Canadian Listing Sponsor due diligence proves that could have taken up to six months to complete. The waiver of the Canadian Listing Sponsor is largely based on the fact that the Company’s Board of Directors and key management personnel have considerable TSX listed company experience. Once the Regulator (British Columbia Securities Commission) has approved the prospectus, we will push approach the TSX for final listing approval. Prospectus Regulator Review InnoMed Tech is pleased to advise that it has filed the updated Prospectus on Monday July 17, 2023. This updated prospectus reflects new patent awards and financing arrangements. The audited financial statements to December 31, 2023 and six-month interim financial statement to June 30, 2023 are included in draft awaiting final clearance from the statutory auditor, RSM Canada. The financial statements included for the first time the following: i) the fist securitisation debt finance loan drawdowns; ii) appointment of Ernst & Young Luxembourg (top four audit firm) to conduct the financial; accounting treatments for cash subscriber shareholder Top-Up investment protections; and iii) the claw back of 6.5 million common shares awarded to insiders incorrectly awarded before April 15, 2021, Patents The Company’s strategy is to target the investment in patent application processes to those jurisdictions that present the probable markets for production and/or use. Patent awards have now been received for Canada, Eurasia, Morocco, Panama, Japan, Philippines and Australia. InnoMed Tech continues to progress the United States of America and European patent applications having made significant progress to date. PureFlowCath Medical Device Update The Company completed Phase One (and extension), Proof of Concept, work with Paragon Medical in May 2023. Phase Two will be a significant investment to produce a working prototype suitable for the commencement of testing. The Company is currently scoping the detailed work to be conducted to effectively engage with potential developers ensuring stewardship of the Company funds. The Company’s aim is to progress as quickly as practical but due to the novelty of our product the process of specification, tendering and negotiation will take a few months. Management is aiming to have the contract in place in Q4 2023 but given the complexity it is expected that the contract to develop the Prototype will likely be let early in 2024. Capital Resources to Fund Working Capital The Company has agreed terms with CIC Fund Securitisation S.A. to provide debt finance of up to Euro €5,000,000 (the “Facility̶ The Company has preserved working capital funds by agreement with CIC Capital Ltd. to convert nine months Transaction Advisor fees to debt notes thereby preserving the outflow of working capital funds. This was an independently approved related party transaction. We are pleased to advise that existing shareholders have provided additional equity investment during 2023 at the same price per share of 29 cents with a warrant. Invested Value Risk Minimisation The Company has provided a risk minimisation mechanism for equity subscribers through a “Top-Up” provision should the listed share price be lower than 29 US cents per share. The Top-Up option will fall away after 30-days post trading. The Top-Up provision allows for additional shares (rounded up), with warrants, to be issued at a discount of 20% to the current trading price if trading price in less that 29 US cents per share to compensate for the notional reduction of investment. Value Accretion Innomed Tech is advancing quickly, progressing on product and corporate fronts, focused on delivering useful medical products and thereby increased shareholder value. Peer analysis shows that on completion of the prototype to medical product, FDA approvals and further patent award will deliver on the potential for significant value accretion. Peer analysis with medical device companies with approved medical device and all FDA approvals is between US$4 to $16 per share. Please note this is a forward-looking statement and shareholders should not rely on such statements. www.InnomedTec.com Billy Williams Disclosure Officer/Director +1 251 786 4695 BWilliams@InnomedTec |
Posted at 26/7/2023 13:20 by papillon Luckily I'm not a shareholder in either CICC, or CICG, sparty1 |
Posted at 25/7/2023 19:45 by papillon CICC will have been delisted for 10 years in early May 2024CICG will have been delisted for 10 years in January 2026. |
Posted at 31/5/2023 21:44 by papillon SYME didn't stay at 14p for long. I can't predict share prices, but I'd hazard a guess that the share price will close tomorrow lower than today. |
Posted at 23/5/2023 21:48 by papillon Well the SYME share price recovered most of it's loss on the day. According to the 14 day RSI the SYME share price is overbought, but that could continue for sometime.Following the spike up in the SYME share price at the end of July 2022 it took 2 months for the share price to drop back to the same price as existed pre the spike. Will history repeat itself? Possible, but I can't predict share prices so I'm not even prepared to try. |
Posted at 15/8/2022 10:33 by sparty1 This share holder up date is response to questions being asked by our shareholders:1 What is the expected listing date?; 2 What is the management performance since appointment on April 15, 2020?;and 3. What is the expected share trading price and share holder return? 1. What is the expected listing date? The Company’s is not permitted or unable to promote an expected listing date. The regulatory reviews of the prospectus are largely complete save for the review of any requirement for updated financial statements. The listing timetable is now solely on the regulatory review outcomes and our response to any additional requirement that are imposed beyond the standard form prospectus that the Company has provided. The Company can disclose matters that have impacted the timing to date. Initial reviews have required ten (10) different sets of financial statements to meet regulatory acceptance given the complexity of transactions and intangible asset valuations. The initial filing was made in January 2021. A three-month delay in late 2021 was due to the request to calculate and disclose a cost in the financial statements for the shareholder protection provision (Top Up) against a potential share price falling below US$0.29. This required a complex derivative calculation and an analysis of the volatility of listed peer companies over the preceding two years. The Derivative Cost is disclosed in the financial statements from Q3 2021. Q3 Financial statements reviewed with the auditor is a precedent interim financial statements and has been valuable in timely filings of Q1 2022 and most recently Q2 2022. The Company has engaged with the Regulator throughout the first quarter. Subsequent to Q1 2021, the Regulator paused review until the completion of the independent audit of the 31 December 2021 Financial Statements that was completed in May 2021. In June 2022 there was a requirement for Q1 2022 Financial Statement to be submitted. The Company at the time of this shareholder update has completed Q2 2022 Financial statements and will be filed shortly. the Regulator also requires the quarterly financial statements to be submitted with a confirmation and comfort letter from the Company auditors, again a time and cost imposition. RSM Canada, the Company auditors, have been very focused to speed up their review processes required because of the significant judgements required in our financial statement disclosures through derivative analysis. The depth of knowledge that they now have is of great assistance to the Company’s ability to respond to the Regulator’s requirements more quickly. The Regulator has now requested the Share Purchase Agreement (former Class two members) be updated to meet their requirements. Those affected will receive an email of changes requested by the regulators. Usual practice for a Company of our status is for the Regulator to require a Sponsor. Due to the cost involved, the fact that the prospectus is non-offering (not raising capital) and the experience of the Company’s management and Board of Directors, the Company will seek a derogation not to have a regulated Sponsor. There is no certainty the derogation will be granted. The Appointment and Sponsor review can take up to three months. 2. What is the management performance since appointment on April 15, 2020? The Company is pleased to provide the achievements of management since their appointment which became effective from April 15, 2020 where they replaced Board control from Innovative Medicine Partners, LLC (“IMP”). Management and the Board of Directors have focussed on implementing proper stewardship on capital raised, noting that cash of US$3,800 at the time of assuming their positions was not sufficient to pay liabilities. The objectives of the team, consisting of new and some legacy people, were and remain to increase shareholder value by: · Establishing a governance framework · Addressing legacy issues / conflict-of-interest / administrative lapses · Preparing and secure listing of the Company · Securing funding for activities and to meet liabilities · Securing Patents in appropriate jurisdiction · Acquiring FDA approval · Completing design and development of the product The table 2 below details the Boards performance and effective use of investor funds. The average monthly burn rate (amount of expenses per month) post new management is US$65,930 compared to US$186,167 under previous management. Tabe 2 3. What is the Company target share price? The peer companies used for the derivative analysis by the auditor as detailed in question 1 above shows at our current progression a share price between US$2.20 TO US$36.20 with a share price volatility of 22.2% (price rise or fall) The Companies target share price is: I) Short term US$0.60 to $1.20 II) medium term US$2.80 to $8.50 Please note that the Warrants issued has a doubling effect on return and investors.For future tax consideration investors should seek appropriate tax advice and can use the following method of Investment return calculation: Shares issued + warrants multiply by share price subtract money paid = investment return For US $100,000 subscription, shares issued 344,828: 344,828 (shares) + 344,828 (warrants) x 1.20 (target share price) – 200,000 (investment plus warrant exercise) = US$627,586 (capital again after deduction of cash investment) www.InnomedTec.com Billy Williams Disclosure Officer/Director +1 251 786 4695 BWilliams@InnomedTec Key service organisations: |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
